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Co-blockade of PD-1 and CTLA-4
increases benefits in cancer
immunotherapy but also its toxicity.
Berezhnoy et al. constructed a bispecific
DART molecule to deliver safer and
potentially more effective co-blockade by
targeting CTLA-4 inhibition to tumors.
MGD019 demonstrates encouraging
activity in tumors traditionally
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Combination immunotherapy with antibodies directed against PD-1 and CTLA-4 shows improved clinical
benefit across cancer indications compared to single agents, albeit with increased toxicity. Leveraging the
observation that PD-1 and CTLA-4 are co-expressed by tumor-infiltrating lymphocytes, an investigational
PD-1 x CTLA-4 bispecific DART molecule, MGD019, is engineered to maximize checkpoint blockade in the
tumor microenvironment via enhanced CTLA-4 blockade in a PD-1-binding-dependent manner. In vitro,
MGD019 mediates the combinatorial blockade of PD-1 and CTLA-4, confirming dual inhibition via a single
molecule. MGD019 is well tolerated in non-human primates, with evidence of both PD-1 and CTLA-4
blockade, including increases in Ki67+CD8 and ICOS+CD4 T cells, respectively. In the ongoing MGD019
first-in-human study enrolling patients with advanced solid tumors (NCT03761017), an analysis undertaken
following the dose escalation phase revealed acceptable safety, pharmacodynamic evidence of combinato-
rial blockade, and objective responses in multiple tumor types typically unresponsive to checkpoint inhibitor
therapy.
INTRODUCTION
Cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and pro-
grammed cell death protein 1 (PD-1) inhibit a variety of T cell
functions, such as proliferation, cytokine production, and cyto-
toxicity. Induced upon activation, CTLA-4 expression by T cells
leads to their functional inhibition by multiple mechanisms,
including competition with CD28-mediated activation1 and
removal of co-stimulatory ligands from antigen-presenting cells
(APCs).2 CTLA-4 is also constitutively expressed by regulatory
T cells (Tregs) and is essential to maintain self-tolerance.
Knockout of CTLA-4 in Tregs does not affect their survival, but it
does eliminate their suppressive function.3 When expressed by
T lymphocytes, among other cells, PD-1 acts as an inhibitory
molecule that reduces cytotoxicity and cytokine production.
Localized expression of programmed death ligand 1 (PD-L1)
and PD-L2 is induced in prolonged inflammatory environments,
where it protects affected tissues from immune attack4 and pre-
serves chronically activated T cells in a suppressed yet viable
state.5 Mechanistic studies revealed that, while both CTLA-4
and PD-1 suppression rely on the CD28 co-stimulation
pathway,6 the 2 molecules have separate but complementary
roles in T cell regulation.
Both PD-1 and CTLA-4 are co-opted by tumors to enable im-
mune evasion, the escape of otherwise immunosensitive tumors
from T cell-mediated lysis.7 Antibody-mediated blockade of
CTLA-4 or PD-1 mediates antitumor activity in murine models.7,8
In the clinic, both PD-1- and CTLA-4-targeted therapies have
yielded therapeutic benefit, while their combination has demon-
strated improved responses in advanced melanoma, non-small
cell lung carcinoma (NSCLC), renal cell carcinoma, hepatocellu-
lar carcinoma, and microsatellite instability-high colorectal can-
cer.9–13 Inhibiting PD-1 predominantly re-activates exhausted
CD8 T cells14 and their precursors,15 without induction of new
antitumor effectors. While PD-1/PD-L1 axis blockade has
become a mainstay of cancer therapy,16,17 the magnitude and
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durability of its clinical effects strongly depend on preexisting tu-
mor-specific T cell populations18 and could be further
augmented by the expansion of effector T cells in periphery.19,20
CTLA-4 inhibition by the monoclonal antibody (mAb) ipilimumab
induces polyclonal T cell activation and expansion, yielding a
more diversified antitumor immune response,21,22 accompanied
by the expansion of inducible T cell co-stimulator (ICOS)high CD4
T cells.23 The complementary pharmacodynamic mechanisms
of PD-1 and CTLA-4 blockade underlie the improved clinical
efficacy observed upon combinatorial blockade of both check-
points, with ipilimumab plus the anti-PD-1 mAb, nivolumab, re-
sulting in enhanced antitumor activity beyond levels achievable
by either blockade alone.24 Clinical improvements in combina-
tion therapy, however, were accompanied by the increased fre-
quency and severity of treatment-related adverse events
(TRAEs). Fifty-five percent of patients receiving the combination
of ipilimumab and nivolumab experienced severe (i.e., gradeR3)
TRAEs, a significant increase compared to 16% for nivolumab
and 27% for ipilimumab when administered alone.24 Beyond
the potential medical consequences, severe TRAEs often neces-
sitate treatment alterations (e.g., reduction of recommended
doses, discontinuation of treatment, immunosuppressive ther-
apy), introducing factors that may limit the therapeutic benefits
of combinatorial blockade in some patients.
Novel strategies, such as targeting immune interventions to
the tumor microenvironment (TME)25,26 or Fc effector domain
modulation,27,28 may increase treatment benefit and reduce im-
mune-mediated toxicity. In mouse models, the antitumor effects
of anti-CTLA-4 treatments were related to blockade of CTLA-4 in
the TME and tumor-draining lymph nodes, while adverse effects
were associated with the Fc-dependent effector function of anti-
CTLA-4 blockers in healthy tissues.26
Agents capable of optimal co-blockade of these two check-
points should preserve PD-1 neutralization in all compartments
together with maximal CTLA-4 inhibition in the TME, without
depletion of Treg in normal tissues. While such differential
blockade is beyond the reach of conventional antibodies, pur-
pose-engineered molecules could provide a solution. To
address this challenge, we engineered a tetravalent bispecific
PD-1 x CTLA-4 molecule (MGD019) by using the bispecific
DART platform. The molecule was designed to fully block
PD-1 while exerting increased CTLA-4 blockade on dual-ex-
pressing cells, such as tumor-infiltrating lymphocytes (TILs), to
preferentially direct the co-blockade activity to the TME. Built
on an immunoglobulin G4 (IgG4) backbone, MGD019 showed
no Fc-mediated effector function while augmenting human
T cell activation in vitro. MGD019 was well tolerated in cynomol-
gus monkeys and yielded preliminary evidence of clinical activity
with acceptable safety in heavily pre-treated, advanced solid tu-
mor cancer patients.
RESULTS
Cells Co-expressing PD-1 and CTLA-4 Abound in the
TME Compared to Normal Tissues
Dual in situ hybridization (ISH) and multicolor flow cytometry
were used to define the expression pattern of PD-1 and CTLA-
4 in tumors, peripheral blood, and healthy tissues (Figure 1).
ISH analyses of an ovarian cancer tumor tissue microarray
(TMA) revealed detectable PD-1+ and CTLA-4+ cells at varying
levels in most specimens (Figure 1A). On a cellular basis,
CTLA-4 and PD-1 expression was associated primarily with tu-
mor immune infiltrate, with cells co-expressing both molecules
readily detected (Figure 1B). In contrast, analysis of a 35-healthy
adult tissue TMA revealed no expression of PD-1 or CTLA-4, with
the exception of lymphoid organs (thymus, tonsils, and lymph
nodes) and rare occurrences in the stroma of colon and
pancreas (data not shown). Notably, PD-1 and CTLA-4 expres-
sion in normal lymphoid tissues was observed in distinct,
spatially separated cell populations, in contrast to the pattern
of co-expression observed in TILs (Figure 1B). Digital quantita-
tion confirmed a higher proportion of PD-1/CTLA-4 double-pos-
itive cells in ovarian (Figure 1B), breast, lung, colon, and rectal
cancer specimens relative to those observed in normal lymphoid
tissues (Figures 1C and S1). Flow cytometry studies comparing
circulating T cells from healthy donors and TILs from patients
with various cancers confirmed cell surface protein expression
(Figures 1D and 1E). On average, 14.6% of TILs expressed
both PD-1 and CTLA-4, 51.8% expressed PD-1 alone, 2.8% ex-
pressed CTLA-4 alone, and 30.8% did not express either
protein. This observation is in line with a prior report of a high
occurrence of PD-1 and CTLA-4 expression on TILs.29 Interest-
ingly, a small but detectable fraction (<0.25%) of circulating
T cells from tumor patients co-expressed PD-1 and CTLA-4,
while no circulating double-positive cells were detected in
healthy donors (Figures 1D and 1E). These data indicate that
cells co-expressing PD-1 and CTLA-4 are prevalent in the TME
but virtually absent in healthy tissues. This observation further
implies that targeting dual PD-1-/CTLA-4-expressing cells may
provide an opportunity for selective checkpoint blockade in the
TME, while relatively reducing effects in normal tissues.
Engineering and Characterization of MGD019, a PD-1 x
CTLA-4 Bispecific Molecule Featuring Complete
Blockade of PD-1 and Variable Inhibition of CTLA-4
To build a molecule capable of stringent, uniform blockade of
PD-1 and conditional blockade of CTLA-4, we selected a high-
affinity, clinically validated anti-PD-1 mAb30,31 and an anti-
CTLA-4 mAb with ligand-blocking properties similar to that of
ipilimumab (see Method Details) as a precursor for the PD-1
and CTLA-4 arms, respectively. A PD-1 x CTLA-4 bispecific
molecule was constructed on the DART platform32 in a symmet-
ric, tetravalent 2 3 2 format (designated MGD019; Figure 2A),
with a hinge-stabilized IgG4 backbone to limit Fc-dependent
effector functions, including antibody-dependent cell cytotox-
icity (ADCC). The choice of Fc domain was primarily driven by
the desire to limit the potential depletion of PD-1+ activated
T cells and to avoid the adverse effects of Treg depletion.
MGD019 binds cell surface expressed PD-1 and blockss PD-
L1 binding with a potency profile superimposable with that of
its retifanlimab precursor (Figure 2B) or a replica of nivolumab
(Figure S2A). When a bivalent 1 3 1 format was used, however,
PD-1 ligand-binding blockade was significantly compromised
(Figure S3), indicating avidity requirements to maintain maximum
PD-1 inhibition on single-positive cells. In contrast to the behavior
of the PD-1 binding arm, CTLA-4-binding and B7.1-binding




blockade were reduced in the MGD019 format relative to the
parental mAb (Figure 2C) or a replica of ipilimumab (Figure S2B).
However, maximal blockade of B7.1 ligand/CTLA4 interaction on
CTLA4-only expressing cells was achieved at higher concentra-
tions. Higher binding saturation levels were observed on PD-1/
CTLA-4 double-positive cells, consistent with the ability of
MGD019 to interact with PD-1 and CTLA-4 independently of
each other (Figure 2E).
A key feature of bispecific molecules is the potential for simul-
taneous antigen recognition in cis on the same cell, amechanism
that can promote binding cooperativity through avidity. Enzyme
complementation following MGD019-mediated co-ligation of
PD-1 and CTLA-4 expressed on the surface of model cells
confirmed that the DART molecule can simultaneously co-
engage PD-1 and CTLA-4 on the same cell (Figure 2D). The avid-
ity contributed by cis-mode binding to the 2 antigens resulted in
greatly enhanced MGD019-mediated blockade of CTLA-4 activ-
ity on dual-expressing cells, with a 100-fold increase in po-
tency compared to the CTLA-4 parental mAb (Figure 2E). In
contrast, avidity-driven cooperativity did not contribute substan-
tially to PD-1/PD-L1 binding blockade (Figure S3C). The obser-
vation is consistent with MGD019-mediated ligand blockade of
PD-1 exceeding that of CTLA-4 (Table S1). To confirm that
enhanced CTLA-4 blockade on dual-expressing cells was driven
by anchoring MGD019 via its PD-1 arm, the interaction was
competed with an excess of the parental PD-1 mAb. As pre-
dicted, in the presence of 10-fold excess anti-PD-1 mAb,
MGD019 demonstrated 10-fold reduction in CTLA-4 blocking
activity (Figure 2F). In summary, MGD019 can independently
engage and block PD-1 and CTLA-4 on cells expressing one
or the other checkpoint molecule and mediate PD-1 expres-
sion-dependent enhancement of CTLA-4 blockade through
PD-1 anchoring on co-expressing cells (Figure 2G).
To determine the ability to overcome dual PD-1/CTLA-4
checkpoint suppression in T cells, MGD019 was evaluated
side by side with PD-1 and CTLA-4 mAb combinations in an
engineered reporter assay (Figure 3A) and in primary T cell acti-
vation assays (Figure 3B). In both assay systems, MGD019 sup-
ported dual checkpoint pathway reversal to the same level as
mAb combinations, including replicas of ipilimumab and nivolu-
mab. Furthermore, MGD019 mediated the reversal of T cell sup-
pression in mixed lymphocyte reactions and superantigen recall
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Figure 1. Cells Co-expressing PD-1 and CTLA-4 Are More Prevalent in the Tumor Microenvironment
(A) In situ RNA hybridization of PD-1 and CTLA-4 probes in ovarian cancer tumor cores (N = 21) analyzed using RNAscope and quantified with HALO software.
Each square represents an individual core, with red and blue circles representing the indicated frequency of PD-1 and CTLA-4 expression, respectively. The first
square shows PD-1 and CTLA-4 expression in a non-malignant ovary sample.
(B) In situ RNA hybridization of PD-1 (red) and CTLA-4 (blue) probes visualized by RNAscope in representative tumor microarray core or healthy tonsil samples.
(C) Fraction of cells co-expressing PD-1 and CTLA-4 RNA detected by ISH in lymphoid organs from healthy donors (N = 7) or tumor samples from randomly
selected patients (N = 12). Means and standard deviations (SDs) are shown.
(D) Peripheral blood mononuclear cells (PBMCs) from healthy donors (N = 8) and PBMCs (N = 27) or dissociated tumor cells (DTCs) (N = 7) from patients with
various cancers were stained for PD-1 and CTLA-4 expression and analyzed by flow cytometry. Box and whiskers plots depict the minimum, first quartile,
median, third quartile, and maximum. Gated on viable CD45+/CD3+ cells.
(E) Representative fluorescence-activated cell sorting (FACS) images from (D) gated on viable T cells.
See also Figure S1.








Figure 2. MGD019 Molecular Structure and Bispecific Binding to PD-1 and CTLA-4
(A) MGD019 is a tetravalent bispecific (2 3 2) Fc-bearing DART molecule.
(B) Binding of MGD019 (red diamonds), parental PD-1 mAb retifanlimab (blue squares), parental CTLA-4 mAb 4B6 (green triangles), or isotype control (black
circles) to Jurkat/PD-1 cells and blockade of PD-L1 binding to the cells.
(C) Binding to Jurkat/CTLA-4 cells and blockade of B7-1 binding to the cells.
(D) Re-activation of b-galactosidase (b-gal) upon co-engagement of PD-1 and CTLA-4 by MGD019 in PathHunter PD-1+CTLA-4+ assay. Error bars depict
standard errors of the mean (SEMs).
(E) Binding to in vitro-stimulated, PD-1+/CTLA-4+ primary T cells and blockade of B7.1 binding to Jurkat PD-1+/CTLA-4+ cells.
(F) Blockade B7.1 binding to Jurkat PD-1+/CTLA-4+ byMGD019 or CTLA-4mAbs alone or in the presence of a 103 concentration of competing PD-1mAbs (open
red diamonds and purple crosses, respectively).
(G) Interaction of MGD019 with single- and dual-expressing cells. Average (EC50) values of PD-1 (blue) and CTLA-4 (yellow) ligand binding blockade (Table S1).
Representative experiments out of R3 independent repeats are shown in (B)–(F).
See also Table S1 and Figures S2 and S3.




assays, with activity again comparable to that of mAb combina-
tions (Figure S4). In 25% of healthy donors, in whom PD-1 or
CTLA-4 blockadewith individual blockingmAbs did not substan-
tially affect staphylococcal enterotoxin B (SEB)-driven T cell acti-
vation, MGD019 but not the combination of 2 mAbs enhanced
interleukin-2 (IL-2) release, although the magnitude of the effect
was variable between donors. Unlike ipilimumab, MGD019 did
not reduce the number of FoxP3+ cells in vitro (Figures 3C and
3D).
MGD019 Is Well Tolerated in Non-human Primates
The toxicity profile, pharmacokinetic (PK), and pharmacody-
namic activities of MGD019 were evaluated in cynomolgus mon-
keys, a relevant cross-reactive species. MGD019 binding affinity
to cynomolgus monkey PD-1 or CTLA-4 is in the range of the hu-
man target antigens. Repeat intravenous (i.v.) administrations
(4 weekly doses) of MGD019 were well tolerated at dose levels
of 10, 40, and 100 mg/kg (Table 1). In-life effects were limited
to an increased incidence of soft/watery feces at R40 mg/kg
and minor hematological changes atR10 mg/kg. Spleen weight
parameters were increased compared to controls for males at
doses ofR40mg/kg and females at doses ofR10mg/kg, which
correlated microscopically with generalized lymphoid hyperpla-
sia characterized by increased numbers of lymphocytes
affecting all compartments of the lymphoid tissues. All of the ef-
fects were reversible following a 10-week recovery period and
were not considered adverse. The no-observed-adverse-effect
level was 100 mg/kg, the highest dose tested.
MGD019 demonstrated linear PK (half-life7 days) across the
dose range tested (Figure 4A). All animals within the individual
dose groups achieved comparable exposure to MGD019 during
the first dose interval; however, exposure decreased in some
A B
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Figure 3. PD-1 x CTLA-4 Bispecific Inhibitor Enhances T Cell Activation
(A) Dual reporter cell line (Jurkat-PD-1/CTLA-4 cells) and artificial APCs (Raji-PD-L1/B7 cells) were co-cultured in the presence of MGD019 (red diamonds), its
parental PD-1 (blue squares) or CTLA-4 (green triangles) mAbs, their combination (purple crosses), nivolumab33 ( blue blue crosses), ipilimumab (yellow triangles),
or their combination (tan hexagons) and isotype control (black circles). Representative experiments out of 3 independent repeats are shown.
(B) Mean fold change of IL-2 concentrations in the samples treated with 10 mg/mL of MGD019 or control mAbs relative to samples treated with control IgG plus
indicated concentrations of SEB. The experiments were performed individually with PBMCs from healthy donors (N = 39). Error bars depict SEMs. Inset: subset of
donors (N = 9/39) with reduced effects to PD-1 blockade (IL-2 fold change [f.c.] < 2) demonstrate enhanced responses to MGD019; 25 ng SEB dose is shown.
Mean values are shown. Paired t-test with two tailed p value calculation was used.
(C) PBMCs from healthy donors were activated in vitrowith anti-CD3 and treated with MGD019 or replicas of ipilimumab featuring its original IgG1 Fc or replaced
with IgG4. Fraction of FoxP3+ T cells was measured after 48-h incubation. Representative graphs of 18 independent replicates are shown.
(D) Mean values of CD4+FoxP3+ cells measurements across multiple (N = 6) independent repeats using PBMCs of different donors (N = 2).
See also Figure S4.




animals during the fourth dose interval due to the appearance of
anti-drug antibodies (ADAs). The level of MGD019 binding to PD-
1-expressing circulating T cells correlated with its serum con-
centration (Figure 4B). A dose-dependent shift in the relative pro-
portion of circulating T cells with a memory-like phenotype at the
expense of naive T cells (Figure 4C and S5C), together with an
increase in the fraction of splenic ICOS-expressing CD4+
T cells (Figure 4D), were observed in MGD019-treated animals,
while no change in tissue-resident or circulating Treg populations
were apparent (Figure 4E). These pharmacodynamic changes
are consistent with previously reported effects of CTLA-4
blockade in vivo.34,35
To distinguish the effects of dual PD-1 plus CTLA-4 check-
point blockade in vivo from that of PD-1 blockade alone, the ef-
fects of MGD019 in cynomolgus monkeys were compared to
those of its parental PD-1 mAb. Both molecules were associated
with evidence of T cell proliferation (Figures 4F and S5B),
although MGD019-treated animals had more prominent
changes in the Ki67+ T cell fraction and showed T cell expansion
in the spleen (Figure S5A), indicating the additional impact of
CTLA-4 blockade by the DART molecule.
First-in-Human Study Highlights Clinical Activity and
Correlative Pharmacodynamics
Patients with advanced, previously treated solid tumors of any
histology were enrolled in a Phase I study of MGD019 at esca-
lating doses of 0.03, 0.1, 0.3, 1, 3, 6, and 10 mg/kg administered
as 30-min i.v. infusions every 3 weeks in a 3 + 3 + 3 design. Thir-
ty-three patients (median age 61 years; 51.5% male; 3 median
prior lines of therapy) representing 21 different advanced solid
tumor types were treated before the data cutoff, including 13 pa-
tients (39.4%) previously receiving checkpoint inhibitor therapy.
MGD019 demonstrated linear kinetics with a half-life of
12.4 days. Simulated multiple-dose PK profiles indicate that
doses R3 mg/kg maintain serum trough concentrations of
MGD019 comparable to those of ipilimumab or nivolumab (Fig-
ures 5A and S6A). MGD019 bound circulating T lymphocytes
(Figure 5B) occupying and blocking PD-1 for durations propor-
tional to dose and serum concentrations (Figure 5C). MGD019
administration was associatedwith enhanced proliferation of pe-
ripheral CD8+ T cells, but no associated changes in Treg popula-
tion (Figure 5D). Furthermore, a dose-dependent upregulation of
ICOS on circulating CD4+ T cells was observed (Figures 5E and
S6C), with the highest frequency and positivity in patients treated
at a dose R3 mg/kg.
MGD019 was generally well tolerated up to the top predefined
dose level of 10 mg/kg, with no dose-limiting toxicities (DLTs)
observed. As such, the maximum tolerated dose (MTD) was
not exceeded or defined. After enrolling additional patients to
further explore PK/pharmacodynamic relationships and clinical
activity, intolerability at 10 mg/kg became evident. As of the
data cutoff of April 1, 2020, TRAEs occurred in 26/33 (78.8%) pa-
tients, most commonly fatigue (24%), nausea, arthralgia, pruri-
tus, and rash (18% each). The rate of grade R3 TRAEs was
24.2% (Table 2; Figure S6D). Among 8 patients treated at
10 mg/kg, notable immune-related adverse events included
grade 3 events of myocarditis, enterocolitis, and maculopapular
rash. No grade 4 or 5 TRAEs were observed. Table 2 displays
TRAEs observed in R5% of patients, as well as adverse events
of special interest (AESI) occurring at lower frequencies.
Treatment-related serious adverse events (SAEs) included en-
teritis, enterocolitis, pneumonitis, and myocarditis (n = 1 each)
and occurred at dose levelsR3 mg/kg; all of the patients recov-
ered without sequelae after discontinuation of MGD019 and
appropriate treatment. Infusion-related reactions (IRRs) were
observed (n = 5, 15.2%) and were mild to moderate in severity.
Among 25 response-evaluable patients, objective responses
per Response Evaluation Criteria in Solid Tumors version 1.1
were observed in 4 patients (including 1 unconfirmed response),
with tumor types conventionally unresponsive to checkpoint in-
hibition. These 4 patients were among 13 response-evaluable
patients treated at doses R3 mg/kg (Figure 5G) and each
demonstrated ICOS upregulation on circulating CD4+ T cells.
Confirmed objective responses occurred in patients with micro-
satellite-stable colorectal cancer (Figure 5F), metastatic type AB
thymoma (both partial responses [PRs]), and metastatic castra-
tion-resistant prostate cancer (complete response [CR]) with
resolution of elevated pre-treatment prostate-specific antigen.
In addition, an unconfirmed partial response was observed in
an anti-PD-L1-refractory serous fallopian tube carcinoma pa-
tient with a >50% reduction of CA-125. Nine patients had stable
disease as a best response.
DISCUSSION
The engineering of a molecule capable of simultaneous
blockade of PD-1 and CTLA-4 must be informed by both clinical
considerations and biological context. Given the critical clinical
role and favorable safety profile that systemic PD-1/PD-L1 axis
blockade plays in tumor immunotherapy, an ideal combinatorial
compound should not compromise the ability of the molecule to
block the interaction between PD-1 and its ligands. In contrast,
CTLA-4 blockade may carry greater propensity for untoward ef-
fects, which could be limited by conditioning the CTLA-4 arm to





















1 5/5 D5W – – – 0/6 0/4
2 5/5 MGD019 10 [14/[42 Y9/Y10 0/6 0/4
3 5/5 MGD019 40 [57/[61 Y4 /[48 2/6 0/4
4 5/5 MGD019 100 [41/[88 [50 /[28 5/6 0/4
D5W, 5% dextrose for injection; F, female; M, male.
aMean absolute spleen weight percentage increase ([) or decrease (Y)
from control values at days 25 and 93 necropsy; 3 animals per sex per
group at day 25 and 2 per sex per group at day 93.
bIncidence of minimal generalized splenic lymphoid hyperplasia at days
25 and 93 necropsy: number of animals with finding (n)/number of ani-
mals examined (N). Hyperplasia was characterized by the increased
numbers of lymphocytes affecting all compartments of the lymphoid tis-
sues, although follicles tended to be normal size.




block preferentially in the context of PD-1/CTLA-4 dual-express-
ing cells present in the TME. MGD019 provides PD-1 blockade
in vitro comparable to stand-alone anti-PD-1 molecules (i.e., re-
tifanlimab, its precursor molecule, or nivolumab) and a variable
degree of CTLA-4 blockade. In PD-1/CTLA-4+ cells, MGD019
blockade of CTLA-4 ligand binding is reduced compared to
that mediated by anti-CTLA-4 mAbs, while in TIL-like dual-ex-
pressing cells, the potency of CTLA-4 blockade can increase
by 2 orders of magnitude (Figure 2), in agreement with an avid-
ity-driven effect.36 Consistent with this observation, dual check-
point blockade by MGD019 in primary T cell models provided an
enhanced effect in a subset of donors selected for poor
response to PD-1 blockade in vitro.
MGD019, by virtue of an IgG4 Fc region, has a limited capacity
for Fc-mediated ADCC, sparing potential depletion of targeted
cells, which would have included effector T cells in addition to
Treg cells. The impact of Treg depletion on the efficacy and safety
of ipilimumab is still uncertain27,37,38; enabling the Fc of anti-
CTLA-4 agents to mediate depletion, however, has been linked
toboth activity39 and adverse effects26 inmousemodels. Avoiding
CTLA-4-mediated Treg depletion while maintaining strong CTLA-4
blockade in the TME may contribute to improving safety, while
maintaining the efficacy associated with CTLA-4 antagonism.
Furthermore, the main immunosuppressive effect of tumor-asso-
ciated Treg cells can be ascribed to CTLA-4 functional activity.
3
MGD019 blockade of CTLA-4 in the TME may be sufficiently
strong to compensate for the absence of Treg depletion due to
increased avidity in dual-expressing cells and ability to create a
high local concentration of PD-1 anchored CTLA-4 inhibitor.
The PK characteristics of MGD019 in cynomolgus monkeys
were similar to those of humanized mAbs in this species, which
is consistent with the possibility of dosing every 2 or 3 weeks in
humans. More important, this animal model provided evidence
of both PD-1 and CTLA-4 blockade, with a safety profile that
compares favorably to published data of the combination of ipi-
limumab and nivolumab in this species.
A B C
FED
Figure 4. MGD019 Provides Dual Checkpoint Blockade In Vivo
(A and B) Cynomolgus monkeys (5 females and 5 males per group) were infused with 10, 40, or 100 mg/kg MGD019 at days 1, 8, 15, and 22. Mean serum
concentrations of MGD019 and mean percentages of PD-1+ cells with MGD019 detectable at cell surface by flow cytometry are shown. Error bars depict SEMs,
vertical dotted lines indicate dose administration, and the horizontal dotted line marks 100% cell-surface binding.
(C–E) Splenocytes obtained from cynomolgus monkeys treated with 4 weekly administrations of MGD019 or vehicle control and necropsied 3 days after the last
infusion were stained for CD28/CD95 (C), ICOS (D), or CD25/FoxP3 (E) expression. Means and SDs are shown. Gated on CD45+/CD3+/CD4+ cells.
(F) Cynomolgus monkeys were infused i.v. Q1W for 3 weeks with 75mg/kgMGD019 (3 males/3 females) or, in a separate study, 100mg/kg parental PD-1mAb (2
males/2 females). Ki67 expression on circulating CD4+ T cells was quantified by flow cytometry. Means and SEMs are depicted.
See also Figure S5.




Compared to animals treated with retifanlimab, the anti-PD-1
mAb precursor, animals treated with MGD019 demonstrated
pharmacodynamic changes consistent with dual PD-1 plus
CTLA-4 blockade, with no excess toxicity. These included an
increased number of proliferating (Ki67+) circulating T cells,
accompanied by increased spleen weights attributed to T cell
expansion. MGD019-treated animals also show circulating
T cells with phenotypes associated with CTLA-4 blockade,
including the induction of ICOS+ CD4 cells23 and the expansion
of the memory-like phenotype.35 Consistent with its design, the
IgG4-bearing molecule showed no reduction in tissue Treg
numbers. Our results indicate a range of immunostimulating
properties of MGD019 independent of Treg depletion. Adminis-




Figure 5. Clinical Benefits of Dual PD-1 and CTLA-4 Blockade Mediated by MGD019
(A) Simulated multiple-dose PK profiles for the 3, 6, and 10 mg/kg Q3W regimens with observed pre-dose and post-dose data superimposed. Target con-
centration overlaid as dashed line.
(B) MGD019 receptor occupancy for CD4+ T cells collected 21 days after second infusion (green) compared to measured immediately after third infusion (blue)
(N = 22). Means and SDs are depicted.
(C) Binding ofMGD019-competing FACSmAbs to circulating T cells in patients treated withMGD019 before first dose (gray) and 8 (blue) and 22 (green) days later
(N = 28). Bars indicate minimum to maximum intervals.
(D) Fraction of proliferating CD8+ T cells (N = 6) and regulatory T cells (N = 7) observed in cryopreserved PBMCs of patients treated with 3 (brown), 6 (yellow), and
10 (blue) mg/kg MGD019 collected at the indicated days. Paired t-test with two tailed p value calculation was used.
(E) ICOS expression on peripheral blood CD4+ T cells measured before (gray) and 8 days after (blue) first infusion of indicated doses of MGD019 (N = 28) or
patients treated with a PD-1 based therapy not containing CTLA-4 blockade (obrtained from an independent study) that serves as a Control (N=4). Bars indicate
mean values.
(F) Scans of the patient with microsatellite stable (MSS) colorectal cancer (CRC) obtained ~15 weeks after treatment initiation, demonstrating resolution of a 3.0-
cm subcarinal lymph node.
(G) Waterfall plot of RECIST 1.1 response evaluable patients treated with 3, 6, and 10 mg/kg MGD019. # indicates previous treatment with checkpoint inhibitor
and + indicates patients currently staying in the study.
See also Figure S6.




evidence of watery feces at the highest doses. By contrast, the
combination of ipilimumab and nivolumab resulted in persistent
diarrhea and gastrointestinal tract inflammation at doses as low
as 3mg/kg ipilimumab plus 10mg/kg nivolumab, with the 10mg/
kg ipilimumab plus 50 mg/kg nivolumab dose exceeding the
highest non-severely toxic dose.40
A relatively low first-in-human dose of 0.03 mg/kg was chosen
due to the potential for unexpected toxicity of dual blockade. The
experience in the dose escalation phase of the ongoing first-in-
human evaluation of MGD019 has demonstrated acceptable
safety of MGD019 at doses up to 10 mg/kg without protocol-
defined dose-limiting toxicities (i.e., prespecified events occur-
ring during the first 28 days after initial MGD019 administration).
However, subsequent to additional enrollment at the top dose
level (i.e., 10 mg/kg), intolerability was observed in patients
with delayed grade 3 TRAEs, notably events of myocarditis
and enterocolitis occurring in separate patients with onset at
study days 74 and 81, respectively. Immune-related adverse
events have been manageable, and patients have recovered
without sequelae after immunosuppressive treatment and
MGD019 interruption or discontinuation, as appropriate.
Although the maturing MGD019 clinical safety data correspond
to a small population treated to date at various dose levels (n =
33), the overall tolerability and incidence of grade R3 TRAEs
compares favorably to published ipilimumab plus nivolumab
safety data.10 HumanPK ofMGD019was confirmed to be similar
to that of recombinant mAbs, including a linear profile and a
12.4-day half-life. Full PD-1 blockade was achieved at doses
R1 mg/kg every 3 weeks (Q3W). ICOS upregulation, a surrogate
measure of CTLA-4 blockade (CTLA-4+ cells are undetectable in
the circulation; data not shown), was induced by MGD019 at
doses R3 mg/kg. The association between the CTLA-4
blockade biomarker (ICOS induction) and objective clinical re-
sponses suggests that CTLA-4 blockade may drive the clinical
benefits of the bispecific in this patient population. The role of
ICOS induction as a response biomarker warrants further
investigation.
The frequency of severe TRAEs and overall safety profile of
MGD019 is favorable for this class of agents. At doses
<10 mg/kg, the safety profile has been generally consistent
with that of anti-PD-1 monotherapy. At doses R3 mg/kg,
MGD019 demonstrated evidence of anti-tumor activity in this
pre-treated patient population, with responses observed in pa-
tients with lowmutational burden colorectal cancer or those hav-
ing failed prior checkpoint inhibitor therapy.
The encouraging preclinical and initial clinical data support
further clinical investigation of the potential of MGD019, a pur-
pose-designed single agent to inhibit both PD-1 and CTLA-4,
to improve patient outcomes through increased tolerability and
therapeutic responses.
Table 2. Treatment-Related Adverse Events in R5% of Patients and AESI in Order of Decreasing Frequency
TRAE



















7 (100) 2 (28.6) 3 (100) 1 (33.3) 6 (75.0) 3 (37.5) 26 (78.8) 8 (24.2)
Fatigue 2 (28.6) 0 0 0 3 (37.5) 1 (12.5) 8 (24.2) 1 (3.0)
Nausea 1 (14.3) 0 0 0 3 (37.5) 0 6 (18.2) 0
Pruritus 1 (14.3) 0 1 (33.3) 0 3 (37.5) 0 6 (18.2) 0
Arthralgia 2 (28.6) 0 0 0 2 (25.0) 0 6 (18.2) 1 (3.0)
Rash
maculo-papular
2 (28.6) 0 1 (33.3) 1 (33.3) 2 (25.0 1 (12.5) 6 (18.2) 2 (6.1)
IRRb 0 0 0 0 2 (25.0) 0 5 (15.2) 0
Myalgia 2 (28.6) 0 0 0 0 0 4 (12.1) 0
Dry mouth 1 (14.3) 0 0 0 1 (12.5) 0 3 (9.1) 0
Hypothyroidismb 2 (28.6) 0 0 0 0 0 3 (9.1) 0
Vomiting 1 (14.3) 0 0 0 1 (12.5) 0 3 (9.1) 0
Lipase increased 1 (14.3) 1 (14.3) 0 0 0 0 2 (6.1) 2 (6.1)
Diarrhea 1 (14.3) 0 0 0 1 (12.5) 0 2 (6.1) 0
Pneumonitisb 2 (28.6) 0 0 0 0 0 2 (6.1) 0
Decreased
appetite
0 0 0 0 2 (25.0) 0 2 (6.1) 0
Pyrexia 0 0 0 0 2 (25.0) 0 2 (6.1) 0
Myocarditisb 0 0 0 0 1 (12.5) 1 (12.5) 1 (3.0) 1 (3.0)
Enteritisb 1 (14.3) 1 (14.3) 0 0 0 0 1 (3.0) 1 (3.0)
Enterocolitisb 0 0 0 0 1 (12.5) 1 (12.5) 1 (3.0) 1 (3.0)
IRR, infusion-related reaction.
aNo grade 4 or grade 5 TRAEs observed as of the data cutoff.
bAdverse event of special interest.





While the initial clinical data indicate thatMGD019 iswell tolerated
and yields anti-tumor activity, additional patients will need to be
evaluated to substantiate these preliminary findings and deter-
mine the consistency and durability of observed responses. The
present study is also limited by the unavailability of on-treatment
tumor biopsies. The evaluation of such biopsies will facilitate the
dissection of the MGD019-mediated mechanism of action in the
TME, pursuant to the hypothesis of MGD019 preferentially target-
ing dual PD-1/CTLA-4-expressing T cells in the context of CTLA-4
blockade. Future studies will also explore correlations of
response with baseline biomarkers, including PD-1 and CTLA-4
co-expression on TILs and peripheral pharmacodynamic re-
sponses to PD-1 and CTLA-4 blockade, as well as attempt to
define patient populations with potential improved therapeutic
benefit to MGD019.
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et al.; CheckMate 214 Investigators (2018). Nivolumab plus Ipilimumab
versus Sunitinib in Advanced Renal-Cell Carcinoma. N. Engl. J. Med.
378, 1277–1290.
13. Overman, M.J., Lonardi, S., Wong, K.Y.M., Lenz, H.J., Gelsomino, F.,
Aglietta, M., Morse, M.A., Van Cutsem, E., McDermott, R., Hill, A., et al.
(2018). Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA
Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic
Colorectal Cancer. J. Clin. Oncol. 36, 773–779.
14. Gros, A., Tran, E., Parkhurst, M.R., Ilyas, S., Pasetto, A., Groh, E.M., Rob-
bins, P.F., Yossef, R., Garcia-Garijo, A., Fajardo, C.A., et al. (2019). Recog-
nition of human gastrointestinal cancer neoantigens by circulating PD-1+
lymphocytes. J. Clin. Invest. 129, 4992–5004.
15. Im, S.J., Hashimoto, M., Gerner, M.Y., Lee, J., Kissick, H.T., Burger, M.C.,
Shan, Q., Hale, J.S., Lee, J., Nasti, T.H., et al. (2016). Defining CD8+ T cells
that provide the proliferative burst after PD-1 therapy. Nature 537,
417–421.
16. Ribas, A., and Wolchok, J.D. (2018). Cancer immunotherapy using check-
point blockade. Science 359, 1350–1355.
17. Esfahani, K., Roudaia, L., Buhlaiga, N., Del Rincon, S.V., Papneja, N., and
Miller, W.H., Jr. (2020). A review of cancer immunotherapy: from the past,
to the present, to the future. Curr. Oncol. 27 (Suppl 2), S87–S97.
18. Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J., Rob-
ert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014).
PD-1 blockade induces responses by inhibiting adaptive immune resis-
tance. Nature 515, 568–571.
19. Wu, T.D., Madireddi, S., de Almeida, P.E., Banchereau, R., Chen, Y.J.,
Chitre, A.S., Chiang, E.Y., Iftikhar, H., O’Gorman, W.E., Au-Yeung, A.,
et al. (2020). Peripheral T cell expansion predicts tumour infiltration and
clinical response. Nature 579, 274–278.
20. Yost, K.E., Satpathy, A.T., Wells, D.K., Qi, Y., Wang, C., Kageyama, R.,
McNamara, K.L., Granja, J.M., Sarin, K.Y., Brown, R.A., et al. (2019).
Clonal replacement of tumor-specific T cells following PD-1 blockade.
Nat. Med. 25, 1251–1259.
21. Robert, L., Tsoi, J., Wang, X., Emerson, R., Homet, B., Chodon, T., Mok,
S., Huang, R.R., Cochran, A.J., Comin-Anduix, B., et al. (2014). CTLA4
blockade broadens the peripheral T-cell receptor repertoire. Clin. Cancer
Res. 20, 2424–2432.
22. Postow, M.A., Manuel, M., Wong, P., Yuan, J., Dong, Z., Liu, C., Perez, S.,
Tanneau, I., Noel, M., Courtier, A., et al. (2015). Peripheral T cell receptor
diversity is associated with clinical outcomes following ipilimumab treat-
ment in metastatic melanoma. J. Immunother. Cancer 3, 23.
23. Liakou, C.I., Kamat, A., Tang, D.N., Chen, H., Sun, J., Troncoso, P., Log-
othetis, C., and Sharma, P. (2008). CTLA-4 blockade increases IFN-
gamma-producing CD4+ICOShi cells to shift the ratio of effector to regu-
latory T cells in cancer patients. Proc. Natl. Acad. Sci. USA 105, 14987–
14992.
24. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao,
C.D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al.
(2015). Combined Nivolumab and Ipilimumab or Monotherapy in Un-
treated Melanoma. N. Engl. J. Med. 373, 23–34.
25. Schrand, B., Berezhnoy, A., Brenneman, R., Williams, A., Levay, A., Kong,
L.Y., Rao, G., Zhou, S., Heimberger, A.B., and Gilboa, E. (2014). Targeting
4-1BB costimulation to the tumor stroma with bispecific aptamer conju-
gates enhances the therapeutic index of tumor immunotherapy. Cancer
Immunol. Res. 2, 867–877.
26. Pai, C.S., Simons, D.M., Lu, X., Evans, M., Wei, J., Wang, Y.H., Chen, M.,
Huang, J., Park, C., Chang, A., et al. (2019). Tumor-conditional anti-CTLA4
uncouples antitumor efficacy from immunotherapy-related toxicity. J. Clin.
Invest. 129, 349–363.
27. Arce Vargas, F., Furness, A.J.S., Litchfield, K., Joshi, K., Rosenthal, R.,
Ghorani, E., Solomon, I., Lesko, M.H., Ruef, N., Roddie, C., et al. (2018).
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 An-
tibodies. Cancer Cell 33, 649–663.e4.
28. Ha, D., Tanaka, A., Kibayashi, T., Tanemura, A., Sugiyama, D., Wing,
J.B., Lim, E.L., Teng, K.W.W., Adeegbe, D., Newell, E.W., et al.
(2019). Differential control of human Treg and effector T cells in tumor
immunity by Fc-engineered anti-CTLA-4 antibody. Proc. Natl. Acad.
Sci. USA 116, 609–618.
29. Wei, S.C., Levine, J.H., Cogdill, A.P., Zhao, Y., Anang, N.A.S., Andrews,
M.C., Sharma P, Wang J, Wargo J A, Pe’er D, and Allison J P. (2017).
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Check-
point Blockade. Cell 170, 1120–1133.e17.
30. Gringnani, G., Burgess, M., Depenni, R., Guida, M., Spagnolo, F., Spada,
F., De Braud, F., Pulini, J., Shankar, S., Tian, C., and Lebbé, C. (2020).
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REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
CD3_BV711 (clone UCHT1) Biolegend Cat#: 300464; RRID: AB_2566036
CD3_PE-Cy7 (clone SP34-2) BD Biosciences Cat#: 557749; RRID: AB_396855
CD3_V450 (clone SP34-2) BD Biosciences Cat#: 560351; RRID: AB_1645168
CD4_APC (clone OKT4) Biolegend Cat#: 317416; RRID: AB_571945
CD4_APC-H7 (clone SK3) BD Biosciences Cat#: 641398; RRID: AB_1645732
CD4_BV605 (clone OKT4) Biolegend Cat#: 317438; RRID: AB_11218995
CD4_PE-cy7 (clone SK3) BD Biosciences Cat#: 557852; RRID: AB_396897
CD4_V450 (clone L200) BD Biosciences Cat#: 560811; RRID: AB_2033927
CD8_FITC (clone SK1) BD Biosciences Cat#: 347313; RRID: AB_400279
CD8_V500 (clone RPA-T8) BD Biosciences Cat#: 560774; RRID: AB_1937325
CD25_PE (clone M-A251) Biolegend Cat#: 356134; RRID: AB_2564145
CD25_PE-cy7 (clone M-A251) BD Biosciences Cat#: 557741; RRID: AB_396847
CD28_PE (clone CD28.2) BD Biosciences Cat#: 555729; RRID: AB_396072
CD56_BV570 (clone 5.1H11) Biolegend Cat#: 362540; RRID: AB_2565918
CD95_APC (clone DX2) BD Biosciences Cat#: 340481; RRID: AB_400519
CD159a_APC (clone Z199) Beckman Cat#: A60797; RRID: AB_10643105
CTLA-4_Dazzle694 (clone BNI3) Biolegend Cat#: 369616; RRID: AB_2632878
CTLA4_PECy7 (clone L3D10) Biolegend Cat#: 349913; RRID: AB_2563097
Cyno CD45_PerCP (clone D058-1283) BD Biosciences Cat#: 558411; RRID: AB_397080
FoxP3_FITC (clone PCH101) eBiosciences Cat#: 11-4776-42; RRID: AB_1724125
FoxP3_PE (clone 259D/C7) BD Biosciences Cat#: 560046; RRID: AB_1645508
Goat anti-human IgG_APC (polyclonal) Jackson Immunoresearch Cat#: 109-005-098; RRID: AB_2337541
ICOS_PE (clone C398.4A) Biolegend Cat#: 313508; RRID: AB_416332
ICOS_PE-Cy7 (clone C398.4A) Biolegend Cat#: 313520; RRID: AB_10643411
Ki-67_Alexa647 (clone B56) BD Biosciences Cat#: 561126; RRID: AB_10611874
Ki67_PE-Cy7 (clone Ki-67) Biolegend Cat#: 350526; RRID: AB_2562872
PD 1_PE (clone eBioJ105) eBiosciences Cat#: 12-2799-42; RRID: AB_11042478
PD-1_AF647 (clone 1F8) this paper N/A
PD-1_APC (clone eBioJ105) eBiosciences Cat#: 17-2799-41; RRID: AB_10598512
anti-EK_biotin (clone 2-A5) This paper N/A
PD-1 mAb (parental) This paper N/A
CTLA-4 mAb (parental) This paper N/A
PD-1 x CTLA-4 1x1 DART molecule This paper N/A
PD-1 x CTLA-4 2x2 DART molecule
(MGD019)
This paper N/A
Nivolumab replica Korman et al.33 Nivolumab
Ipilimumab replica 41 Ipilimumab
Biological Samples
Peripheral blood from healthy donors STEM Express N/A
Dissociated tumor cells Discover Life Sciences N/A
Human normal tissue array (digital image) Advanced Cell Diagnostics Cat# TA2361f
Human ovarian cancer tissue array (digital
image)
Advanced Cell Diagnostics Cat# ACD012
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REAGENT or RESOURCE SOURCE IDENTIFIER
Human colon cancer tissue array Advanced Cell Diagnostics Cat# ACD017
Human rectal cancer tissue array Advanced Cell Diagnostics Cat# ACD024
Human lung cancer tissue array Advanced Cell Diagnostics Cat# ACD019
Human breast cancer tissue array Advanced Cell Diagnostics Cat# ACD025
MGD019 Ph1 patient’s peripheral blood This paper N/A
Cynomolgus monkey splenocytes MPI Research N/A
Chemicals, Peptides, and Recombinant Proteins
Highly Purified Staphylococcal Enterotoxin
B (SEB)
Toxin Technology Cat# BT202
Human B7-1 protein (biotinylated) BPS Bioscience Cat# 71114
Human PD-L1 protein (biotinylated) BPS Bioscience Cat# 71105
Recombinant human IL-2 Peprotech Cat# 200-02
Recombinant human IL-4 Peprotech Cat# 200-04
Recombinant human GM-CSF Peprotech Cat# 300-03
Fixable Viability Dye eFluor 780 eBioscience Cat# 50-169-66





CTLA-4 blockade bioassay (propagation
model)
Promega Cat# JA3005




Pathhunter cell culture kit DiscoverX Cat# 92-3103G
Fixation/Permeabilization Solution Kit BD Biosciences Cat# 554714
Lysing Buffer BD Biosciences Cat# 555899
70mm Cell Strainer Corning Costar Cat# 352350
ACK lysis buffer Quality Biological Inc Cat# 118156101CS
autoMACS Running Buffer Miltenyi Biotech Cat# 130-091-221
TruCount tubes BD Biosciences Cat# 340334
Steady Glo luciferase substrate Promega Cat# E2520
BioFX TMB substrate SurModics Cat# TMBW-1000-01
Ficoll Paque Plus GE Healthcare Cat# 17-1440-03
RPMI-1640 Media GIBCO Cat# 11875-093
Fetal bovine serum VWR Cat# 79068-085
CD14 MicroBeads, human Miltenyi Biotech Cat# 130-050-201
CD4 MicroBeads, human Miltenyi Biotech Cat# 130-045-101
Dynabeads CD3 (human) ThermoFisher Scientific Cat# 11151D
Human interferon gamma ELISA kit R&D systems Cat# DY285B
Human IL-2 ELISA kit R&D systems Cat# DY202
Experimental Models: Cell Lines
Jurkat/PD-1 Promega Cat# J1252
Jurkat/CTLA-4 Promega Cat# JA3005
Jurkat/PD-1+CTLA-4 Promega Cat# CS1978D04
PD-1/CTLA4 Receptor Dimerization Cell
Line
DiscoverX Cat# 83-0010C3
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Paul A.
Moore (moorep@macrogenics.com).
Materials Availability
Limited quantities of newly generated materials associated with the paper are available under MTA.
Data and Code Availability
This study did not generate/analyze datasets or code.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines and Cell Culture
Cell lines expressing human PD-1 (Jurkat/PD-1), human CTLA-4 (Jurkat/CTLA-4) and co-expressing human PD-1 together CTLA-4
(Jurkat/PD-1+CTLA-4) were provided by Promega (Madison, USA) as a part of bioassay systems and cultured according to manu-
facturer’s instructions. U20S cells engineered to express PD-1 and CTLA-4 were obtained from DiscoveRx (Fremont, USA) and
cultured using media provided by the manufacturer.
Human and Non-human Primates Tissue Samples
Normal human tissue microarray and tumor microarrays of ovarian, breast, lung, colon, rectal cancer samples were provided
by Advanced Cell Diagnostic (Newark, USA). Heparinized healthy donor blood was purchased from StemExpress (Folsom,
USA). PBMCs were isolated by density centrifugation in Ficoll Paque (GE Healthcare, Chicago, USA). Cryopreserved dissoci-
ated tumor cells from patients with lung, renal, ovarian, and colorectal carcinomas were obtained from Discovery Life Sci-
ences, Inc. (Los Osos, USA). The use of these materials does not require IRB approval. Sections of spleen were collected dur-
ing necropsy from cynomolgus monkeys used in the GLP toxicology study. Spleen sections were transported overnight at
ambient temperature in serum-free RPMI media. Pieces were mechanically separated using 70 mM cell strainers into single
cell suspensions.
Cynomolgus Monkeys
The nonclinical toxicology study was conducted at Charles River Laboratories (CRL), Mattawan, USA, in accordance with US Food
and Drug Administration Good Laboratory Practice Regulations for Nonclinical Laboratory Studies (21 CFR Part 58), the US
Department of Agriculture Animal Welfare Act (9 CFR Parts 1, 2, and 3), and the Guide for the Care and Use of Laboratory Animals,
Institute of Laboratory Animal Resources. The study protocol was approved by the CRL Institutional Animal Care and Use
Committee.
MGD019 Phase 1 Study Participants
The clinical study entitled A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD019, a Bispecific DART Protein
Binding PD-1 and CTLA-4 in Patients with Unresectable or Metastatic Neoplasms was approved by IntegReview IRB and registered
on https://www.clinicaltrials.gov (Identifier: NCT03761017). Male (n = 17) and female (n = 16) patients (median age 61 years) with his-
tologically proven, unresectable, locally advanced or metastatic solid tumors for whom no approved therapy with demonstrated clin-
ical benefit is available or patients who are intolerant to standard therapy. Measurable disease, Eastern Cooperative Oncology Group
performance status 0-1, life expectancy > 12 weeks.
Continued






FlowJo 10 (with Flow AI plugin) FlowJo 10.6.2
GraphPad Prism 8 GraphPad Software 8.3.1
Aperio ImageScope 11 Leica Biosystems 11.2.0.780
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Quantification of PD-1 and CTLA-4 mRNA expression
RNAscope2.5 HD duplex ISH tissue profiling of PD-1 and CTLA-4 in ovarian, breast, colorectal, lung cancer and normal
tissues was performed by Advanced Cell Diagnostic, Inc. (Newark, USA) according to published protocol. FFPE tumor or
normal tissue cores were mounted on slides that were pretreated with enzyme (protease) prior to hybridization with oligo-
nucleotide probes targeted to the RNA in the sample. A series of wash steps followed, to amplify the signal. In the chro-
mogenic assay, detection is via a chromogenic substrate, which produces a precipitate visible under common bright-field
microscopy at 10-20X magnification, forming distinct red or green dots. Brightfield images were acquired using an Aper-
ioAT2 digital slide scanner equipped with a 40x objective. Software analysis was performed with HALO software (Indica-
Labs, USA) to provide cell by cell quantitative results. Cells expressing two or more hybridization dots for each probe
were considered positive.
Flow Cytometry
Cells were stained with Fixable Viability Dye-780 (Fisher Scientific, Waltham, USA) and FACS Abs (Key Resources Table). PFA-based
fixation/permeabilization buffer system (Invitrogen, Carlsbad, USA) was used for intracellular staining, including FoxP3. Whole blood
from patients treated with MGD019 was collected and stabilized using Cyto-CheX BCT tubes (Streck Corp., La Vista, USA). Staining
was performed in whole blood followed by fixation and red blood cells lysis with Pharm Lyse buffer (BDBiosciences, San Jose, USA).
Samples were analyzed using LSRFortessa cytometer (BD Biosciences, San Jose, USA); at least 20’000 events were collected for
each sample.
Receptor Occupancy Studies
One hundred mL of whole blood samples (per time point/per patient) was incubated with saturating concentration of MGD019 or con-
trol DART, followed by lysis and detection ofMGD019 by biotinylated anti-drugmAb (anti-EK coil) and Strep-PE in ‘‘MGD019-spiked’’
and control samples. After subtraction of background fluorescence (Strep-PE only), receptor occupancy (RO) values were calculated
as a fraction of maximal binding capacity: RO = [MFI(PE) of untreated sample – background MFI(PE)]/[(MFI(PE) of ‘‘MGD019-spiked’’
sample – background MFI(PE)].
In vivo PD-1 Blockade Studies
Patients whole blood samples (per time point/per patient) were incubated with commercial, APC-labeled, MGD019-competing anti-
PD-1 mAb (clone J105, eBioscience, San Diego, USA). Percent of CD3+CD4+ lymphocytes stained with commercial anti-PD-1 mAb
before and after MGD019 administration was recorded for each patient.
Molecular Design of MGD019
MGD019 is a tetravalent Fc-bearing DART molecule comprising two PD-1 and two CTLA-4 binding domains.32 The PD-1 binding
domain is derived from retifanlimab, which was generated by immunizing mice with His-tagged human PD-1 extracellular domain
and standard hybridoma technology. The murine mAb was humanized by CDR grafting. The CTLA-4 binding domain is derived
from humanmAb 4B6.41 The Fc domain of MGD019 is of an IgG4 isotype with S228Pmutation to prevent dissociation of the Fc dimer
andM252Y/S254T/T256Emutations to enhanceMGD019’s in vivo half-life. MGD019was produced in ExpiCHO or CHO-K1 cells and
purified by Protein A affinity chromatography, followed by size exclusion chromatography or ion exchange chromatography using
standard procedures.
Primary SEB Assay
Cryopreserved healthy donor PBMC were thawed and plated 105 cells/well in 200 mL of complete RPMI. mAbs and bispecific inhib-
itors were added at fixed concentration (10 ug/mL), and Staphylococcus Aureus Enterotoxin B (SEB, Toxin Technology, Inc., Sara-
sota, USA) was titrated as indicated. Cells were incubated for 96 hours prior to supernatant collection.
SEB Restimulation Assay
Freshly isolated PBMCwere activated with 0.5 ng/mL SEB for 48 hours, followed by extensive washing and restimulation with 0.5 ng/
mL SEB in the presence of test molecules. Supernatants were collected 48 hours after restimulation.
Mixed Lymphocyte Reaction
CD14+ cells were isolated from human PMBC using positive selection kit (Milteniy Biotech, Bergisch Gladbach,
Germany) and cultured for 7 days in vitro in the presence of GM-CSF and IL-4, 100 and 50 ng/mL respectively (PeproTech,
Inc., Rocky Hill, USA). Seven days after plating cells were collected and seeded 2 3 104 per well into 96 well plate. CD4+
T cells were freshly isolated negative selection kit (Milteniy Biotech, Bergisch Gladbach, Germany) from unrelated
donor PBMC and co-plated with APCs in the presence of test molecules. Supernatants were collected at 96 hours after
incubation.




Depletion of Autologous Treg cells
Freshly isolated PBMCwere plated in complete RPMI at 106 cells per mL and stimulated with CD3 beads (Invitrogen, Carlsbad, USA)
in the presence of indicatedmAbs or MGD019 at 1 ug/mL. 48 hours later cells were collected and stained with CD4 and FoxP3mAbs.
Cell Surface Binding and Ligand Blockade
Jurkat/PD-1, Jurkat/CTLA-4 and Jurkat/PD-1+CTLA-4 were generated by stable transfection of parental cells. Primary T cell were
purified fromPBMC using negative selection procedure and stimulated with CD3 beads (both Invitrogen, Carlsbad, USA) in complete
RPMI supplemented with 300 IU/mL of IL-2 (PeproTech, Inc., Rocky Hill, USA) to induce expression of PD-1 and CTLA-4. Cells were
incubated with titrated mAbs or DART molecules and detected with secondary goat anti-human IgG polyclonal antibodies (Jackson
Immunoresearch Laboratories, Inc., West Grove, USA). For competition studies cells were incubated with 1 ug/mL biotinylated re-
combinant B7-1 or PD-L1 (BPS Bioscience, San Diego, USA) in the presence of unlabeled test molecules and detected with Strep-
tavidin/R-PE. Flow cytometry was performed using FACSCanto II cytometer (BDBiosciences, San Jose, USA) in plate format; at least
20’000 events were collected for test well.
MGD019-mediated Ligand Blockade
PD-1, CTLA-4 and PD-1+CTLA-4 bioassay systems were obtained from Promega (Madison, USA) and used according to
manufacturers’ instructions. A CHO-based stimulator line expressing anti-CD3 and checkpoint ligands (PD-L1, B7-1 or both) and
a Jurkat-based reporter cell line were cultured together in the presence of MGD019 or mAbs. Induction of luciferase under control
of NF-AT or IL-2 promoter was detected using Steady Glo substrate. U2OS PD-1/CTLA 4 Dimerization Assay. The PathHunter
dimerization assay (DiscoveRx, Fremont, USA) utilizes the enzyme fragment complementation technology where two split b-gal frag-
ments, which independently had no enzymatic activity, could be formed back into a functional b gal to generate chemiluminescence.
U2OS cells were engineered to stably coexpress fragments-tagged CTLA-4 and PD-1; the dimerization assay was performed in the
presence of test articles at indicated concentrations according to manufacturer’s instructions.
Cynomolgus Monkey Toxicity Study
A4-week, repeat-dose studywas conducted in cynomolgusmonkeys (Macaca fascicularis) to evaluate the toxicity ofMGD019. Forty
cynomolgus monkeys of Chinese origin were randomly assigned to 4 groups (5/sex/group) to achieve similar group mean body
weights. The animals were dosed with the vehicle (5%dextrose injection) or MGD019 at 10, 40, or 100mg/kg via IV infusion for 30mi-
nutes once weekly for a total of 4 doses (days 1, 8, 15, and 22). After the completion of dosing, a subset of animals (2/sex/group)
underwent a 10-week recovery period to evaluate the persistence or delayed occurrence of effects. In-life evaluations included
clinical signs, body weights, food consumption, neurobehavioral, electrocardiographic and ophthalmic examinations, vital signs as-
sessments, clinical chemistry, hematology, urinalysis, PK, ADA, and peripheral blood immunophenotyping. A full necropsy was con-
ducted for all animals, with organs weighed and tissues collected, preserved, and processed for histopathologic evaluation. Samples
of spleen were collected from each animal for splenocyte immunophenotyping.
MGD019 PK studies
Intact MGD019 serum concentrations were measured by bispecific enzyme-linked immunosorbent assay at indicated time points.
Open one- or two-compartment IV infusion model was employed to fit the PK data using actual times and concentrations, actual
infusion times, and nominal doses. Individual first dose data were modeled and weighted reciprocally of predicted concentration
squared (2). For PK simulations mean values of best estimates of the model parameters were used for potential clinical dose range
of 3 to 10 mg/kg and Q3W infusions.
MGD019 Phase 1 Clinical Study
The clinical study entitled A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD019, a Bispecific DART Protein
Binding PD-1 and CTLA-4 in Patients with Unresectable or Metastatic Neoplasms was approved by IntegReview IRB and registered
on https://www.clinicaltrials.gov (Identifier: NCT03761017). Objectives. To characterize safety of MGD019 given IV to patients with
advanced cancers, as well as PK and preliminary antitumor activity of MGD019 using conventional RECIST 1.1 and immune-related
(ir)RECIST.
Enrollment criteria. Patients with histologically proven, unresectable, locally advanced or metastatic solid tumors for whom no
approved therapy with demonstrated clinical benefit is available or patients who are intolerant to standard therapy. Measurable dis-
ease, Eastern Cooperative Oncology Group performance status 0-1, life expectancy > 12 weeks. Study design. MGD019 was eval-
uated in sequential, escalating, weight-based doses ranging from 0.03 mg/kg to 10 mg/kg in successive cohorts of 3 to 9 patients
each in a 3+3+3 design. MGD019 is administered as an IV infusion over 30minutes every 3 weeks during a 24-week Induction Period.
Safety assessment is based on AEs from initiation of study drug through 30 days after last study drug or until start of subsequent
anticancer therapy. Tumor assessments are obtained using CT and/or MRI scans (cutaneous lesions may be measured using cal-
ipers and/or photographs with an included scale). During the Induction Period, tumor assessments occur at 12 and 18 weeks after
treatment initiation. After confirmation of the safety of the dose level, additional patients were added to the 3 and 10mg/kg cohorts to
gather additional safety, PK, and PD data.




QUANTIFICATION AND STATISTICAL ANALYSIS
The unpaired and nonparametricMannWhitney test with two tailed p value calculation was used tomeasure differences between two
groups. For multiple group comparisons, one-way ANOVA or two-way ANOVA was used to determine statistically significant differ-
ences between samples. Measurements were summarized as mean ± SD as noted in figure legends. Experimental sample numbers
(n) are indicated in the figure legends. Additional or alternative statistical analysis methods are described in the individual figure leg-
ends. Graph generation and statistical analysis were performed using GraphPad Prism software (GraphPad, La Jolla, USA).
ADDITIONAL RESOURCES
The First-in-Human clinical trial was registered on www.clinicaltrials.gov (Identifier: NCT03761017) https://clinicaltrials.gov/ct2/
show/NCT03761017
e6 Cell Reports Medicine 1, 100163, December 22, 2020
Article
ll
OPEN ACCESS
